EP2391621A4 - BICYCLIC AMIDE DERIVATIVES FOR ENHANCING SYNAPTIC GLUTAMATERGIC RESPONSES - Google Patents

BICYCLIC AMIDE DERIVATIVES FOR ENHANCING SYNAPTIC GLUTAMATERGIC RESPONSES

Info

Publication number
EP2391621A4
EP2391621A4 EP10736150A EP10736150A EP2391621A4 EP 2391621 A4 EP2391621 A4 EP 2391621A4 EP 10736150 A EP10736150 A EP 10736150A EP 10736150 A EP10736150 A EP 10736150A EP 2391621 A4 EP2391621 A4 EP 2391621A4
Authority
EP
European Patent Office
Prior art keywords
amide derivatives
bicyclic amide
synaptic responses
glutamatergic synaptic
enhancing glutamatergic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10736150A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2391621A2 (en
Inventor
Rudolf Mueller
Leslie J Street
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cortex Pharmaceuticals Inc
Original Assignee
Cortex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cortex Pharmaceuticals Inc filed Critical Cortex Pharmaceuticals Inc
Publication of EP2391621A2 publication Critical patent/EP2391621A2/en
Publication of EP2391621A4 publication Critical patent/EP2391621A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP10736150A 2009-02-02 2010-01-29 BICYCLIC AMIDE DERIVATIVES FOR ENHANCING SYNAPTIC GLUTAMATERGIC RESPONSES Withdrawn EP2391621A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20664209P 2009-02-02 2009-02-02
PCT/US2010/000255 WO2010087981A2 (en) 2009-02-02 2010-01-29 Bicyclic amide derivatives for enhancing glutamatergic synaptic responses

Publications (2)

Publication Number Publication Date
EP2391621A2 EP2391621A2 (en) 2011-12-07
EP2391621A4 true EP2391621A4 (en) 2012-07-25

Family

ID=42396261

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10736150A Withdrawn EP2391621A4 (en) 2009-02-02 2010-01-29 BICYCLIC AMIDE DERIVATIVES FOR ENHANCING SYNAPTIC GLUTAMATERGIC RESPONSES

Country Status (12)

Country Link
EP (1) EP2391621A4 (OSRAM)
JP (1) JP2012516845A (OSRAM)
KR (1) KR20110115139A (OSRAM)
CN (1) CN102369201A (OSRAM)
AU (1) AU2010208646A1 (OSRAM)
BR (1) BRPI1005316A2 (OSRAM)
CA (1) CA2751285A1 (OSRAM)
EA (1) EA018994B1 (OSRAM)
IL (1) IL214392A0 (OSRAM)
MX (1) MX2011008060A (OSRAM)
SG (1) SG173168A1 (OSRAM)
WO (2) WO2010087981A2 (OSRAM)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT651746E (pt) * 1992-07-24 2002-09-30 Univ California Drogas que intensificam as respostas sinapticas mediadas por receptores de ampa
US20020099050A1 (en) * 1993-07-23 2002-07-25 Lynch Gary S. Drugs that enhance synaptic responses mediated by AMPA receptors
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
WO1999021422A1 (en) * 1997-10-27 1999-05-06 Cortex Pharmaceuticals, Inc. Treatment of schizophrenia with ampakines and neuroleptics
CA2685858C (en) * 2007-05-17 2015-11-24 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
AU2008287445A1 (en) * 2007-08-10 2009-02-19 Cortex Pharmaceuticals, Inc. Bicyclic amides for enhancing glutamatergic synaptic responses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
SG173168A1 (en) 2011-08-29
MX2011008060A (es) 2011-09-09
WO2010087980A3 (en) 2011-02-24
EP2391621A2 (en) 2011-12-07
EA018994B1 (ru) 2013-12-30
EA201101162A1 (ru) 2012-01-30
WO2010087981A3 (en) 2011-03-24
WO2010087981A2 (en) 2010-08-05
CA2751285A1 (en) 2010-08-05
CN102369201A (zh) 2012-03-07
AU2010208646A1 (en) 2011-09-01
KR20110115139A (ko) 2011-10-20
BRPI1005316A2 (pt) 2019-09-24
IL214392A0 (en) 2011-09-27
WO2010087980A2 (en) 2010-08-05
JP2012516845A (ja) 2012-07-26

Similar Documents

Publication Publication Date Title
ZA201001691B (en) Bicyclic amides for enhancing glutamatergic synaptic responses
BRPI1008749A2 (pt) Derivados de benzodiazepina
PT2414322T (pt) Derivados de poliamina
IL232570B (en) Bicyclic derivatives of dihydroisoquinoline-1-one
EP2391627A4 (en) BICYCLIC PYRAZOLO HETEROCYCLES
IL202187A0 (en) Di-substituted amides for enhancing glutamatergic synaptic responses
BRPI1013246A2 (pt) derivados de benzofuralina
BR112012002828A2 (pt) derivados de 5-fluorpirimidinona
IL212285A0 (en) Azaindole derivatives
GB201117171D0 (en) Cuvette
IL211241A0 (en) 7-azaindole derivatives
IL219029A0 (en) Pyrazolopyrimidine derivatives
BR112012002810A2 (pt) derivados de n1-acil-5-fluoropirimidinona
ZA201201473B (en) Spirocyclic amide derivatives
ZA201106792B (en) Amide derivative
EP2497914A4 (en) CAM DEVICE
GB2498883B (en) Combustion apparatus
IL219603A0 (en) Imidazopyridine derivatives
EP2447264A4 (en) N-SUBSTITUTED CYCLIC AMINO DERIVATIVE
ZA201200415B (en) Amide derivative
ZA201109283B (en) Protein
IL213827A0 (en) Benzothiazolone derivatives
IL225393A0 (en) History of Indole
SG10201406505WA (en) Methods for the detection of fatty-acylated proteins
GB0912769D0 (en) Combustion apparatus

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110826

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

A4 Supplementary search report drawn up and despatched

Effective date: 20120626

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 451/02 20060101AFI20120620BHEP

Ipc: A61K 31/436 20060101ALI20120620BHEP

Ipc: A61P 25/00 20060101ALI20120620BHEP

Ipc: C07D 498/08 20060101ALI20120620BHEP

Ipc: C07D 413/06 20060101ALI20120620BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 451/02 20060101AFI20140619BHEP

Ipc: C07D 413/06 20060101ALI20140619BHEP

Ipc: A61P 25/00 20060101ALI20140619BHEP

Ipc: A61K 31/436 20060101ALI20140619BHEP

Ipc: C07D 498/08 20060101ALI20140619BHEP

INTG Intention to grant announced

Effective date: 20140721

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20141217

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150429